Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies (CAR-T BANK)

University Hospital Center (CHU)

Status: Enrolling

Conditions: Lymphoma and Acute Lymphoblastic Leukemia

Treatments: Other: additional biological samples during CAR-T CELL treatment

Study type: Observational

Funder types: Other

Identifiers

NCT04290000

RECHMPL19_0345

Details and patient eligibility

About

Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukemia leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met in relapsed or refractory diseases, half of the patients don't respond to this treatment.This can be explained by a low expansion, functional alteration or short persistence of infused cells. Determination of reasons for treatment failure is the first step for optimization of this therapeutics. This project aims to bank blood samples from a cohort of patients treated with CAR-T cell for hematological malignancies in Montpellier University Hospital. Clinical data related to samples will be collected. This samples will be used to determine factors influencing efficacy of CAR-T cells treatments.

Full description

Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukema leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met in relapsed or refractory diseases, half of the patients don't respond to this treatment.This can be explained by a low expansion, functional alteration or short persistance of infused cells. Determination of reasons for treatment failure is the first step for optimization of this therapeutics. This project aims to bank blood samples from a cohort of patients treated with CAR-T cell for hematological malignancies in Montpellier University Hospital. Clinical data related to samples will be collected. This samples will be used to determine factors influencing efficacy of CAR-T cells treatments.

Enrollment: 300 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patient treated by CAR-T cell at the University Hospital of Montpellier

Exclusion criteria

• refusal to sign consent form
• pregnant woman
• major protected

Trial design

300 participants in 1 patient group

hematological malignancies

Description:

hematological malignancies treated with CAR-T Cells

Treatment:

Other: additional biological samples during CAR-T CELL treatment